Keyword: University of Oxford
OxStem named Georg Terstappen chief scientific officer, to help lead its six programs aiming to stimulate stem-cell repair mechanisms in the body.
Brand-new U.K. biotech Izana has kicked off a phase 2a trial of anti-GM-CSF antibody namilumab in ankylosing spondylitis.
Modus Therapeutics raised over 140 million Swedish krona, or about $15.7 million, to advance clinical studies of sevuparin in sickle cell disease.
OVM will use the $12.5 million investment to take vaccines against cervical cancer and other solid tumors into the clinic.
European researchers discovered how drugs bind to the enzyme DHODH, which could lead to more selective cancer drugs.
Nightstar will complete a phase 3 trial of its choroideremia gene therapy and advance two other eye disease candidates through early-stage studies.
Takeda Pharmaceutical has teamed up with Harrington Discovery Institute to support research into treatments for rare diseases.
In this week's EuroBiotech Report, Europe-wide scrap for EMA intensifies, Vifor goes solo post-IPO, Mission bags Fox funding and more.
Mission Therapeutics and the University of Oxford have landed a Michael J. Fox Foundation grant to fund testing of USP30 inhibitors.
Novo Nordisk has committed £115 million ($144 million) to set up a Type 2 diabetes drug discovery center at the University of Oxford.